Manages exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight…. ANDA 200177, held by Lannett Co Inc. Diethylpropion Hydrochloride.
As of Nov 16, 2026, ANDA 200177 (Diethylpropion Hydrochloride), held by Lannett Co Inc, was first approved by FDA on Jul 18, 2011, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Diethylpropion hydrochloride tablets USP, 25 mg are indicated in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of 30 kg/m 2 or higher and who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. Below is a chart of BMI based on various heights and weights. BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows: pounds divided by 2.2 = kg; inches × 0.0254 = meters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 18, 2011 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diethylpropion Hydrochloride25MG · tablet;oral | Diethylpropion Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters